← Back to headlines
Tenax Stock Plummets After Pulmonary Hypertension Drug Fails Phase 3 Trial
Tenax Therapeutics' stock experienced a significant drop following the failure of its pulmonary hypertension drug in a crucial Phase 3 clinical trial.
10 Aug, 14:26 — 10 Aug, 14:26
Sources
Showing 1 of 1 sources
